These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 32955521)

  • 1. Targeting of interleukin-10 receptor by a potential human interleukin-10 peptide efficiently blocks interleukin-10 pathway-dependent cell proliferation.
    Chang CC; Liu CD; Pan SF; Huang WH; Peng CW; Hsu HJ
    Ci Ji Yi Xue Za Zhi; 2020; 32(3):245-253. PubMed ID: 32955521
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Interleukin-10 receptor mutations in children with neonatal onset inflammatory bowel disease: genetic diagnosis and pathogenesis].
    Lu D; Xu Y; Chen Y; Zeng P; Chen H; Zeng H
    Zhonghua Er Ke Za Zhi; 2015 May; 53(5):348-54. PubMed ID: 26080664
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel de novo mutations of the interleukin-10 receptor gene lead to infantile onset inflammatory bowel disease.
    Lee CH; Hsu P; Nanan B; Nanan R; Wong M; Gaskin KJ; Leong RW; Murchie R; Muise AM; Stormon MO
    J Crohns Colitis; 2014 Nov; 8(11):1551-6. PubMed ID: 24813381
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Very early-onset inflammatory bowel disease (IBD) in infancy is a different disease entity from adult-onset IBD; one form of interleukin-10 receptor mutations.
    Shim JO; Seo JK
    J Hum Genet; 2014 Jun; 59(6):337-41. PubMed ID: 24785691
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A peptide derived from interleukin-10 exhibits potential anticancer activity and can facilitate cell targeting of gold nanoparticles loaded with anticancer therapeutics.
    Chang CC; Yang CH; Chuang CH; Jiang SJ; Hwang YM; Liou JW; Hsu HJ
    Commun Chem; 2023 Dec; 6(1):278. PubMed ID: 38102207
    [TBL] [Abstract][Full Text] [Related]  

  • 6. IL-10 Receptor Signaling Empowers Regulatory T Cells to Control Th17 Responses and Protect from GN.
    Diefenhardt P; Nosko A; Kluger MA; Richter JV; Wegscheid C; Kobayashi Y; Tiegs G; Huber S; Flavell RA; Stahl RAK; Steinmetz OM
    J Am Soc Nephrol; 2018 Jul; 29(7):1825-1837. PubMed ID: 29866800
    [No Abstract]   [Full Text] [Related]  

  • 7. Influence of IL-10RA and IL-22 polymorphisms on outcome of hepatitis C virus infection.
    Hennig BJ; Frodsham AJ; Hellier S; Knapp S; Yee LJ; Wright M; Zhang L; Thomas HC; Thursz M; Hill AV
    Liver Int; 2007 Oct; 27(8):1134-43. PubMed ID: 17845543
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antagonistic peptides specifically inhibit proliferation, cytokine production, CD40L expression, and help for IgE synthesis by Der p 1-specific human T-cell clones.
    Fasler S; Aversa G; de Vries JE; Yssel H
    J Allergy Clin Immunol; 1998 Apr; 101(4 Pt 1):521-30. PubMed ID: 9564806
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Constructing a better binding peptide for drug delivery targeting the interleukin-4 receptor.
    Bai XD; Cao XW; Chen YH; Fu LY; Zhao J; Wang FJ
    J Drug Target; 2020 Nov; 28(9):970-981. PubMed ID: 32363946
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Polymorphism of IL-10 receptor β affects the prognosis of multiple myeloma patients treated with thalidomide and/or bortezomib.
    Kasamatsu T; Saitoh T; Ino R; Gotoh N; Mitsui T; Shimizu H; Matsumoto M; Sawamura M; Yokohama A; Handa H; Tsukamoto N; Murakami H
    Hematol Oncol; 2017 Dec; 35(4):711-718. PubMed ID: 27405747
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A potent dimeric peptide antagonist of interleukin-5 that binds two interleukin-5 receptor alpha chains.
    England BP; Balasubramanian P; Uings I; Bethell S; Chen MJ; Schatz PJ; Yin Q; Chen YF; Whitehorn EA; Tsavaler A; Martens CL; Barrett RW; McKinnon M
    Proc Natl Acad Sci U S A; 2000 Jun; 97(12):6862-7. PubMed ID: 10823900
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The siRNA cocktail targeting interleukin 10 receptor and transforming growth factor-β receptor on dendritic cells potentiates tumour antigen-specific CD8(+) T cell immunity.
    Ahn YH; Hong SO; Kim JH; Noh KH; Song KH; Lee YH; Jeon JH; Kim DW; Seo JH; Kim TW
    Clin Exp Immunol; 2015 Jul; 181(1):164-78. PubMed ID: 25753156
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumour necrosis factor and interleukin 10 in blood pressure regulation in spontaneously hypertensive and normotensive rats.
    Segiet A; Smykiewicz P; Kwiatkowski P; Żera T
    Cytokine; 2019 Jan; 113():185-194. PubMed ID: 30539780
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The structural network of Interleukin-10 and its implications in inflammation and cancer.
    Acuner-Ozbabacan ES; Engin BH; Guven-Maiorov E; Kuzu G; Muratcioglu S; Baspinar A; Chen Z; Van Waes C; Gursoy A; Keskin O; Nussinov R
    BMC Genomics; 2014; 15 Suppl 4(Suppl 4):S2. PubMed ID: 25056661
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structure-based Development of Human Interleukin-1β-Specific Antibody That Simultaneously Inhibits Binding to Both IL-1RI and IL-1RAcP.
    Kuo WC; Lee CC; Chang YW; Pang W; Chen HS; Hou SC; Lo SY; Yang AS; Wang AH
    J Mol Biol; 2021 Feb; 433(4):166766. PubMed ID: 33359099
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Functional analysis of the interleukin-5 receptor antagonist peptide, AF18748.
    Rosas M; Uings IJ; van Aalst C; Lammers JW; Koenderman L; Coffer PJ
    Cytokine; 2004 Jun; 26(6):247-54. PubMed ID: 15183842
    [TBL] [Abstract][Full Text] [Related]  

  • 17. De-novo design of complementary (antisense) peptide mini-receptor inhibitor of interleukin 18 (IL-18).
    Bhakoo A; Raynes JG; Heal JR; Keller M; Miller AD
    Mol Immunol; 2004 Nov; 41(12):1217-24. PubMed ID: 15482857
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neonatal Crohn's disease with Oral ulcer as the first symptom caused by a compound heterozygote mutation in IL-10RA: a case report.
    Lv H; Qiao B; Fang L; Yang L; Wang Q; Wu S; Ren P; Li L
    Hereditas; 2019; 156():38. PubMed ID: 31889944
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mapping mouse IL-13 binding regions using structure modeling, molecular docking, and high-density peptide microarray analysis.
    Madala SK; Dolan MA; Sharma D; Ramalingam TR; Wilson MS; Mentink-Kane MM; Masison DC; Wynn TA
    Proteins; 2011 Jan; 79(1):282-93. PubMed ID: 21064130
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nucleotide variation in IL-10 and IL-12 and their receptors and cervical and vulvar cancer risk: a hybrid case-parent triad and case-control study.
    Hussain SK; Madeleine MM; Johnson LG; Du Q; Galloway DA; Daling JR; Malkki M; Petersdorf EW; Schwartz SM
    Int J Cancer; 2013 Jul; 133(1):201-13. PubMed ID: 23280621
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.